

Financial Disclosures

The COPHy Virtual Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of COPHy participants. In doing so, the COPHy Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The COPHy Congress requires all program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The COPHy Congress considers financial relationships to create actual conflicts of interest when Presenters or their immediate family (defined as spouse, domestic partner, parent, child or spouse of child, or sibling or spouse of sibling of the Presenter) have both a financial relationship with a commercial interest and the opportunity to affect the policy of the COPHy EU Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias.

All presenters of CME content should familiarize themselves with the policy of the COPHy EU Congress of CME based on the CME provider of the Congress – the EACCME (<http://www.eaccme.AA/uemspdf/UEMS-2012-30.pdf>).

All COPHy Faculty presenting CME are required to disclose to the activity audience the following information prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial ophthalmic products or providers of commercial ophthalmic services within the past 12 months. The COPHy Congress defines "relevant" financial relationships as those with a commercial ophthalmic interest and the opportunity to affect the content of CME about the products or services of that commercial ophthalmic interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships Reported"

NOTE: All presenters are required to report financial disclosures, using the codes below. An individual's financial disclosures for the COPHy Congress meeting are listed in this Section.

COPHy Financial Disclosure Codes

Category	Code	Description
None	N	No financial relationships reported
Consultant	C	Consultant fee, paid advisory boards Advisor fees for attending a meeting (for the past 1 year)
Employee	E	Employed by a commercial entity
Lecture fees	L	Lecture fees (honoraria), travel fees or reimbursements when Speaking at the invitation of a commercial entity (for the past 1 year)
Equity owner	O	Equity ownership/stock options or publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or providers of commercial ophthalmic services
Patents / Royalty	P	Patents and/or royalties that might be viewed as creating a potential conflict of interest
Grant support	S	Grant support for the past 1 year (all sources) \ Used for this project if this form is an update for a specific talk or publication with no time limitation

Disclosure Information

Financial interest disclosures from program members and others in a position for control content:

Francesco Bandello, Italy

Faculty Member

Allergan	C
Bayer	C
Boehringer Ingelheim	C
Fidia Ssoft	C
Hofmann-La Roche	C
Novartis	C
NTC Pharma	C
SIFI	C
Thrombogenics	C
Zeiss	C

Neil Bressler, USA

Co-Chair, Faculty Member

Bayer	S
Genetech/Roche	S
Novartis	S
Samsung Bioepis	S
Bayer	S

Susan Bressler, USA

Faculty Member

Bayer	S
Biocon	S
Biophytis	S
Boehringer-Ingelheim	S
Genentech	S
Mylan	S
Notal	S
Novartis	S
Merck	S

José Cunha-Vaz, Portugal

Faculty Member

Aerpio Therapeutics	C
Alimera Sciences	C
Allergan	C
Bayer	C
Boehringer Ingelheim	C
Novartis	C
Oxular Limited	C
Zeiss Meditec	C

Marc de Smet, Switzerland

Faculty Member

Financial relationships pending

Peter Kertes, Canada

Faculty Member

Allergan	S
Arctidcx	O
Bayer	C, L, S
Novartis	C, L, S
Regeneron Pharmaceuticals	S
Roche	S

Monica Lovestam-Adrian, Sweden

Faculty Member

Financial relationships pending

Paolo Lanzetta, Italy

Faculty Member

Allegro	C
Bayer	C, S
Centervue	C
Novartis	C

Anat Loewenstein, Israel

Co-Chair, Faculty Member

Allergan	S
Bayer	S
Forsight	S
Notal Vision	S
Novartis	S

William Mieler, USA

Faculty Member

No financial relationships reported N

Michael Stewart, USA

Faculty Member

Allergan	S
Alkahest	L
Bayer	C, L
Kanghong	S
Santen	S

Patricia Udaondo, Spain

RAB, Faculty Member

Alimera	C
Allergan	C
Bausch and Lomb	C
Bayer	C
Brill	C
Graybug Vision	C
Novartis	C
Roche	C, S